markertherapeutics.com Open in urlscan Pro
173.231.242.82  Public Scan

Form analysis
2 forms found in the DOM

GET https://markertherapeutics.com/

<form role="search" method="get" action="https://markertherapeutics.com/" class="searchform search-dropdown"><label class="screen-reader-text" for="s">Search:</label>
  <div class="search-wrap"><input type="text" value="" name="s" class="s" placeholder="Search..."> <button type="submit" class="searchsubmit"><i class="far fa-search"></i></button></div>
</form>

GET https://markertherapeutics.com/

<form role="search" method="get" id="searchform" action="https://markertherapeutics.com/">
  <div><label class="screen-reader-text" for="s">Search:</label>
    <div class="search-wrap"><input type="text" value="" name="s" class="s" placeholder="Search..."> <button type="submit" class="searchsubmit"><i class="far fa-search" aria-hidden="true"></i></button></div>
  </div>
</form>

Text Content

 
 * Contact Us
 * Search:
   
 * 
 * 

Toggle Navigation
 * Search:
   
 * Our Company
   * Our Company
   * Management
   * Board of Directors
   * Scientific Advisory Board
   * Contact Us
 * Product Candidates
   * Pipeline
   * MultiTAA Therapies
 * Our Science
   * MultiTAA Technology
   * Manufacturing
   * Publications
 * Clinical Trials
   * Active Clinical Trials
   * Expanded Access Policy
 * Investors/Media
   * Investors/Media Home
   * News & Events
     * Press Releases
     * Events & Presentations
   * Stock Information
     * Stock Quote & Chart
     * Historic Price Lookup
     * Analyst Coverage
   * Financials & Filings
     * SEC Filings
     * Quarterly Results
     * Annual Reports & Proxies
   * Corporate Governance
     * Documents & Charters
     * Management
     * Board of Directors
     * Scientific Advisory Board
     * Committee Composition
   * Investor Resources
     * Investor FAQs
     * Investor Contact
     * Email Alerts
 * Careers
 * Contact Us
 * 


MARKER THERAPEUTICS


ADVANCING NOVEL T-CELL THERAPIES FOR BLOOD CANCERS AND SOLID TUMORS




PIONEERING A MULTI-ANTIGEN APPROACH

Our multi-antigen targeted T cells are designed to recognize and kill highly
heterogeneous multiple tumor targets without the need for genetic modifications.
Because our therapy does not require lymphodepletion or preconditioning for
patients, our therapy has been shown to consistently induce epitope spreading to
the patient’s own immune system. In clinical studies, our MultiTAA product
candidates have been shown to be safe, contributing to durable anti-tumor
responses.

Our therapy has been used to treat over 150 patients in seven different clinical
trials by our collaborators at the Baylor College of Medicine in both blood
malignancies and solid tumors. Based on these positive results of MultiTAA
product candidates, we are advancing our first company-sponsored study in
post-transplant acute myeloid leukemia in a potentially pivotal Phase 2 study.

Learn more
about our
MultiTAA
technology


NEWS

View All News

 * SEPTEMBER 13, 2022
   
   MARKER THERAPEUTICS AWARDED $2 MILLION GRANT FROM U.S. FDA TO SUPPORT
   MARKER’S PHASE 2 ARTEMIS TRIAL OF MT-401 IN POST-TRANSPLANT AML
   
   Read More

 * SEPTEMBER 8, 2022
   
   MARKER THERAPEUTICS TO PARTICIPATE IN CANTOR FITZGERALD CELL AND GENETIC
   MEDICINES CONFERENCE
   
   Read More

 * AUGUST 11, 2022
   
   MARKER THERAPEUTICS REPORTS Q2 2022 OPERATING AND FINANCIAL RESULTS
   
   Read More

   

    


INSIDE OUR LABS


RENUKA MILLER, PHD

Director of Manufacturing

“Cell therapy is revolutionizing the way cancer and other diseases are treated.
I feel fortunate to be a part of the early stages of cell therapy development.
There’s always something new; there’s always something happening. You’re working
with the building blocks of people––dealing with the variable nature of living
things. There’s so much to discover and that can be challenging, but it’s what
keeps us going.”


SHERIN THOMAS

Quality Control Associate Director

“When I joined Marker, we were setting up the lab and GMP facility, which was a
novel experience that provided substantial exposure to diverse learning
opportunities. My work here is never monotonous, and the experience one gains
every day is incomparable. I am proud of the important role I play in ensuring
that we provide quality product to the patient.”


ANASTASIYA SMITH, PHD

Director of Research and Development

“What drives me is the knowledge that what I’m working on could end up in a
clinic and could actually extend someone’s life or improve someone’s life. I
love cell therapy--the ability to take a piece of the patient, manipulate it in
the laboratory and make their own cells function for them. It makes it feel like
what I’m working on could have a real impact.”


TARA SHAHIM

Senior Scientist, Research & Development

“I have lost loved ones because of cancer and it has always made me think, 'Why
aren't we doing more?' At Marker, we are facing important challenges and
striving to come up with innovative ideas to tackle these head on.”
Next


CLINICAL TRIALS

Learn More

Our MultiTAA T cell product candidates are currently being evaluated in seven
clinical studies across blood derived malignancies and solid tumors.

Target indications include acute myeloid leukemia, non-Hodgkin’s lymphoma,
multiple myeloma and breast cancer.

©2022 Marker Therapeutics, Inc. All Rights Reserved.

 * Sitemap
 * Terms of Use
 * Privacy Policy